Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.

ABSTRACT:

Objective

To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis.

Methods

After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.

Results

Of patients entering the OLE phase,

SUBMITTER: Hauser SL 

PROVIDER: S-EPMC7682822 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature